Condition: Kidney Disease, Chronic · Sponsor: Boehringer Ingelheim
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart disease. After a run-in period, during which participants are confirmed to be receiving clinically appropriate renin-angiotensin system blockade and are established on empagliflozin, they are randomly assigned (by chance) to 1 of 2 groups. One group receives BI 690517 tablets, and the other group receives placebo tablets. Placebo tablets look like BI 690517 but do not contain any medicine. Participants take 1 study tablet once a day, in addition to empagliflozin, for the duration of the study. The doctors document when participants experience worsening of their kidney disease, go to hospital due to heart failure, or die of cardiovascular problems during the study. The time to these events is compared …
This description comes directly from the study's public registry record.
Boehringer Ingelheim · 1-800-243-0127 · clintriage.rdg@boehringer-ingelheim.com
Always discuss trial participation with your own doctor first.
| Apogee Clinical Research | Huntsville, Alabama, United States | Recruiting |
| Southwest Kidney Institute | Surprise, Arizona, United States | Recruiting |
| National Heart Institute | Beverly Hills, California, United States | Not Yet Recruiting |
| Florida Kidney Physicians LLC | Jacksonville Beach, Florida, United States | Recruiting |
| Total Research Group, LLC | Miami, Florida, United States | Recruiting |
| Emory University School of Medicine | Atlanta, Georgia, United States | Not Yet Recruiting |
| Joseph Maxwell Cleland Atlanta VA Medical Center | Decatur, Georgia, United States | Recruiting |
| East Coast Institute For Research LLC | Macon, Georgia, United States | Recruiting |
| Kootenai Research Services | Coeur d'Alene, Idaho, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| University of Kansas Medical Center | Kansas City, Kansas, United States | Recruiting |
| Kansas Nephrology Research Institute, LLC | Wichita, Kansas, United States | Recruiting |
+ 468 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06531824